SCHEMBL953767

SCHEMBL953767

CCOC(=O)c1sc(-c2c(C)nn3ccccc23)nc1C1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.43
ALDH1A1 P00352 3/20 0.43
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43
HSD17B10 Q99714 1/20 0.43
DHODH Q02127 3/20 0.41
OGFRL1 Q5TC84 4/20 0.40
OPRM1 P35372 3/20 0.40
OPRK1 P41145 3/20 0.40
OPRD1 P41143 2/20 0.40
LMNA P02545 1/20 0.39
CDC7 O00311 3/20 0.39
DBF4 Q9UBU7 3/20 0.39
ELANE P08246 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ADORA3 P0DMS8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL954029 0.91 ALDH1A1 (0.42) TSHRALDH1A1GAAHTTHSD17B10
SCHEMBL955453 0.88 TSHR (0.42) TSHRALDH1A1HTTHSD17B10LMNA
SCHEMBL953958 0.87 TSHR (0.42) TSHRALDH1A1HTTHSD17B10LMNA
SCHEMBL953769 0.82 CDC7 (0.59) ALDH1A1LMNACDC7DBF4TRPM8
SCHEMBL952685 0.81 LMNA (0.46) ALDH1A1HSD17B10LMNACDC7DBF4
SCHEMBL957422 0.80 CDC7 (0.59) ALDH1A1HSD17B10DHODHCDC7DBF4
SCHEMBL952070 0.79 CDC7 (0.47) TSHRALDH1A1LMNACDC7DBF4
SCHEMBL952323 0.78 CNR1 (0.39) TSHRKDM4E
SCHEMBL955552 0.78 CDC7 (0.41) ALDH1A1HSD17B10DHODHLMNACDC7
SCHEMBL953761 0.77 CHEK1 (0.36) TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 TSHR 1608/4885ALDH1A1 1687/4885GAA 1418/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 TSHR 2433/4885ALDH1A1 728/4885GAA 1693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.